# Organ and Tissue Authority

Entity Resources and Planned Performance

# Organ and Tissue Authority

[Section 1: Entity Overview and Resources 392](#_Toc71465357)

[1.1 Strategic Direction Statement 392](#_Toc71465358)

[1.2 Entity Resource Statement 393](#_Toc71465359)

[1.3 Budget Measures 393](#_Toc71465360)

[Section 2: Outcomes and Planned Performance 395](#_Toc71465361)

[2.1 Budgeted Expenses and Performance 395](#_Toc71465362)

[Section 3: Budgeted Financial Statements 399](#_Toc71465363)

[3.1 Budgeted Financial Statements 399](#_Toc71465364)

[3.2 Budgeted Financial Statements Tables 400](#_Toc71465365)

## Section 1: Entity Overview and Resources

### 1.1 Strategic Direction Statement[[1]](#footnote-1)

The Australian Government’s Organ and Tissue Donation and Transplantation Authority, also known as the Organ and Tissue Authority (OTA), leads the national program to increase organ and tissue donation for transplantation in partnership with states and territories, the national DonateLife Network, donation and transplantation clinical sectors, eye and tissue banks, and the community. Our purpose is to save and improve the lives of more Australians through optimising potential organ and tissue donation for transplantation.

Under the national program, all governments have committed to increasing Australia’s organ and tissue donation rates, with a focus on delivering best clinical practice in hospitals and encouraging Australians to register and let their family know they want to be a donor.

Since commencement of the national program in 2009, there has been significant growth in organ donation rates, and more than 15,525 Australians have received a life changing transplant. However, the COVID-19 pandemic has directly impacted the national program, resulting in a decrease in donation and transplantation activity.

In 2022–23 and future years, the OTA will continue to work collaboratively with governments, the clinical sector and the community to provide access to high quality donation and transplantation services, and strive to bring donation and transplantation rates back to pre-pandemic levels, and then increase further. To do this, the OTA will focus on 4 key objectives:

* increasing donation for transplantation
* increasing consent rates for deceased organ and tissue donation
* providing specialist support for families involved in the donation process
* enhancing systems and processes to support donation and transplantation.

The OTA will continue to work with the Commonwealth Department of Health and state and territory governments to progress the outcomes of 2 key national reviews – *Analysis of the Australian Tissue Sector* and the *Review of the Australian organ donation, retrieval and transplantation system*. This work includes development of a national eye and tissue sector framework and a national strategy for organ donation, retrieval and transplantation in Australia. The delivery on agreed priorities across the sector will build on the success and learnings of the national donation program.

The OTA is a statutory authority established by the *Australian Organ and Tissue Donation and Transplantation Authority Act 2008* and a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013.*

### 1.2 Entity Resource Statement

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity’s operations) classification.

For more detailed information on special accounts and special appropriations, refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the ‛Budgeted expenses by outcome’ tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: OTA Resource Statement – Budget Estimates for 2022–23 as at Budget March 2022

|  |  |  |
| --- | --- | --- |
|  | **2021–22Estimatedactual**$'000 | **2022–23Estimate**$'000 |
| **DEPARTMENTAL** |  |   |
| Prior year appropriation available | 2,589 | 2,589 |
| **Annual appropriations** |  |  |
| Ordinary annual services (a) |  |  |
| Departmental appropriation (b) | 5,754 | 6,194 |
| s74 retained revenue receipts (c) | - | - |
| Departmental Capital Budget (d) | 261 | 264 |
| Other services (e) |  |   |
| Equity injection | - | - |
| **Total departmental annual appropriations** | **6,015** | **6,458** |
| **Total departmental resourcing** | **8,604** | **9,047** |

Table 1.1: OTA Resource Statement – Budget Estimates for 2022–23 as at Budget March 2022 (continued)

|  |  |  |
| --- | --- | --- |
|  | **2021–22Estimatedactual**$'000 | **2022–23Estimate**$'000 |
| **ADMINISTERED** |  |   |
| Prior year appropriation available | 65 | 65 |
| **Annual appropriations** |  |   |
| Ordinary annual services (a) (f) |  |   |
| Outcome 1 | 45,028 | 49,131 |
| **Total administered annual appropriations** | **45,028** | **49,131** |
| **Total administered resourcing**  | **45,093** | **49,196** |
| **Total resourcing for OTA** | **53,697** | **58,243** |
|  |  |  |
|  | **2021–22** | **2022–23** |
| **Average staffing level (number)** | 29 | 30 |

All figures are GST exclusive.

(a) *Appropriation Act (No. 1) 2022–23.*

(b) $0.224 million will be received through the 2021–22 Annual Appropriation Bill No.3. The annual appropriations received from these bills will be recognised in a future Portfolio Budget (PB) Statements but only after the Bills have received Royal Assent.

(c) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

(d) Departmental Capital Budgets are not separately identified in Appropriation Bill (No. 1) including Supply Act (No. 1) form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

(e) *Appropriation Act (No. 2) 2022–23.*

(f) $3.253 million will be received through the 2021–22 Annual Appropriation Bill No.3. The annual appropriations received from these bills will be recognised in a future PB Statements but only after the Bills have received Royal Assent.

### 1.3 Budget Measures

Budget measures in Part 1 relating to the OTA are detailed in *Budget Paper No. 2* and are summarised below.

Table 1.2: OTA 2022–23 Budget Measures

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   | **Program** | **2021–22** $'000 | **2022–23** $'000 | **2023–24** $'000 | **2024–25** $'000 | **2025–26** $'000 |
| **Supporting our Hospitals — organ matching and clinical quality registries (a)** |
| Organ and Tissue Authority |  |  |  |  |  |  |
| Administered payments | 1.1 | - | - | - | - | - |
| Departmental payments |  | - | - | - | - | - |
| **Total**  |  | **-** | **-** | **-** | **-** | **-** |

(a) Funding for this measure has already been provided for by the Government. OTA is not the lead entity for this measure. Full details of this measure are published under Table 1.2: Department of Health 2022–23 Budget Measures.

## Section 2: Outcomes and Planned Performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs that contribute to government outcomes over the Budget and forward years.

Each outcome is described within this section, together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

**Note:**

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth Performance Framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measures described in Portfolio Budget Statements will be read with broader information provided in an entity’s Corporate Plan and Annual Performance Statement – included in Annual Reports – to provide an entity’s complete performance story.

The OTA’s most recent Corporate Plan and Annual Performance Statement are available at: www.donatelife.gov.au/about-us/strategy-and-performance

### 2.1 Budgeted Expenses and Performance

**Outcome 1**

Improved access to organ and tissue transplants, including through a nationally coordinated and consistent approach and system

#### Program Contributing to Outcome 1

**Program 1.1: A Nationally Coordinated System for Organ and Tissue Donation for Transplantation**

#### Linked Programs

| Other Commonwealth entities that contribute to Outcome 1 |
| --- |
| Department of Health (Health)Program 1.1: Health Research, Coordination and AccessHealth has policy responsibility for organ and tissue donation for transplantation, including the Australian Organ Donor Register, administration of the Supporting Living Organ Donors Program, and national approaches around access to organ donation and transplantation services. |
| Services AustraliaProgram 1.2: Services to the Community – HealthServices Australia administers the Australian Organ Donor Register on behalf of Health. |

#### Budgeted Expenses for the OTA

Table 2.1.1 shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by administered and departmental funding sources.

Table 2.1.1: Budgeted Expenses and Resources for the OTA

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **Program 1.1: A Nationally Coordinated System for Organ and Tissue Donation for Transplantation** |
| Administered expenses |  |   |  |  |  |
| Ordinary annual services (a) | 48,281 | 49,131 | 50,082 | 51,009 | 51,739 |
| Departmental expenses |  |   |  |  |  |
| Departmental appropriation (b) | 5,673 | 5,879 | 5,902 | 5,993 | 6,028 |
| Expenses not requiring appropriation in the Budget year (c) | 760 | 779 | 819 | 757 | 760 |
| Operating loss | - | - | - | - | - |
| **Total for Program 1.1** | **54,714** | **55,789** | **56,803** | **57,759** | **58,527** |
| **Total expenses for Outcome 1** | **54,714** | **55,789** | **56,803** | **57,759** | **58,527** |
|  |  |   |  |  |  |
|   | **2021–22** | **2022–23** |  |  |  |
| **Average staffing level (number)** | 29 | 30 |  |  |  |

(a) *Appropriation Act (No. 1) 2021–22.*

(b) Departmental appropriation combines 'Ordinary annual services Appropriation Bill (No. 1)' and 'Revenue from independent sources (s74)'.

(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expense and audit fees.

#### Planned Performance for the OTA

Table 2.1.2 details the performance measure for the program associated with Outcome 1. It also provides the related key activities as expressed in the current Corporate Plan where further detail is provided about the delivery of the activities related to the program, the context in which these activities are delivered and how the performance of these activities will be measured. Where relevant, details of 2022–23 Budget measures that have created new programs or materially changed existing programs are provided.

Table 2.1.2: Performance Measures for the OTA

|  |
| --- |
| Outcome 1 |
| Improved access to organ and tissue transplants, including through a nationally coordinated and consistent approach and system. |
| Program Objective – Program 1.1: A Nationally Coordinated System for Organ and Tissue Donation for Transplantation |
| Lead the delivery of national systems and processes, and continue to raise community awareness to increase donation transplantation in collaboration with state and territory governments, the DonateLife Network, hospitals, clinicians, and the community. |
| Key Activities |
| * Increase donation for transplantation.
* Increase consent rates for deceased organ and tissue donation.
* Provide specialist support for families involved in the donation process.
* Enhance systems and processes to support donation and transplantation.
 |
| Performance Measures[[2]](#footnote-2) |
| Increase the donation rate of deceased organ donors per million population (dpmp) through delivery of a nationally coordinated and consistent approach. |
| Current Year2021Planned Performance Result  | Budget Year2022 Planned Performance Result  | Forward Estimates2023 Planned Performance Result | Forward Estimates2024 Planned Performance Result | Forward Estimates2025 Planned Performance Result |
| 25 dpmp | 25 dpmp | 25 dpmp | 25 dpmp | 25 dpmp |
| **2021 Performance Result** |
| 16.4 dpmp[[3]](#footnote-3) |

|  |
| --- |
| Increase the rate of consent to organ donation through clinical best practice and community engagement. |
| Current Year2021Planned Performance Result | Budget Year2022 Planned Performance Result | Forward Estimates2023 Planned Performance Result | Forward Estimates2024 Planned Performance Result | Forward Estimates2025 Planned Performance Result |
| ≥70% | ≥70% | ≥70% | ≥70% | ≥70% |
| **2021 Performance Result** |
| 56%[[4]](#footnote-4) |
| Increase the percentage of family donation conversations involving a donation specialist, when the opportunity for donation is raised by clinical staff. |
| Current Year2021Planned Performance Result | Budget Year2022 Planned Performance Result | Forward Estimates2023 Planned Performance Result | Forward Estimates2024 Planned Performance Result | Forward Estimates2025 Planned Performance Result |
| 80% | 80% | 85% | 90% | 90% |
| **2021 Performance Result** |
| 76% |
| Through community awareness and education, increase registrations on the Australian Organ Donation Register (AODR). |
| Current Year2021 Expected Performance Results | Budget Year2022 Planned Performance Results  | Forward Estimates2023–25 Planned Performance Results |
| 87% increase of 349,947 in new annual registrations on the AODR from the previous year (as at 31 December). | 10% increase in new annual registrations on the AODR from the previous year (as at 31 December). | As per 2022. |
| Material changes to Program 1.1 resulting from the following measures:There are no material changes to Program 1.1 resulting from measures. |

## Section 3: Budgeted Financial Statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2022–23 Budget year, including the impact of Budget measures and resourcing on financial statements.

### 3.1 Budgeted Financial Statements

#### 3.1.1 Differences between Entity Resourcing and Financial Statements

This section is not applicable to the OTA.

#### 3.1.2 Explanatory Notes and Analysis of Budgeted Financial Statements

**Departmental Resources**

For the Budget and forward years, the OTA is expecting a break-even position net of unfunded depreciation and amortisation expenses. In 2022–23, the OTA has appropriation revenue of $6.194 million and total expenses are estimated at $6.658 million.

**Administered Resources**

The OTA administers funds associated with the delivery of the Australian Government’s national program to optimise potential organ and tissue donation for transplantation. Funding is provided to jurisdictions to deliver organ and tissue donation services in selected public and private hospitals. State and territory governments use these funds to employ specialised clinical staff – the DonateLife Network – to deliver organ and tissue donation services.

In 2022–23, the OTA has forecast administered expenses of $49.131 million.

### 3.2 Budgeted Financial Statements Tables

Table 3.1: Comprehensive Income Statement (showing net cost of services) for the period ended 30 June

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **EXPENSES** |  |   |  |  |  |
| Employee benefits | 4,135 | 4,278 | 4,280 | 4,455 | 4,482 |
| Supplier expenses | 1,629 | 1,697 | 1,722 | 1,646 | 1,654 |
| Depreciation and amortisation | 655 | 669 | 709 | 639 | 642 |
| Interest on RoU | 14 | 14 | 10 | 10 | 10 |
| **Total expenses** | **6,433** | **6,658** | **6,721** | **6,750** | **6,788** |
| **LESS:**  |  |  |  |  |  |
| **OWN-SOURCE INCOME** |  |  |  |  |  |
| **Revenue** |  |  |  |  |  |
| Sale of goods and rendering of services | - | **-** | - | - | - |
| Other revenue | - | - | - | - | - |
| **Total revenue** | **-** | **-** | **-** | **-** | **-** |
| **Gains** |  |  |  |  |  |
| Other  | 105 | 110 | 110 | 118 | 118 |
| **Total gains** | **105** | **110** | **110** | **118** | **118** |
| **Total own-source income** | **105** | **110** | **110** | **118** | **118** |
| **Net cost of (contribution by) services** | **6,328** | **6,548** | **6,611** | **6,632** | **6,670** |
| Revenue from Government | 5,978 | 6,194 | 6,228 | 6,273 | 6,316 |
| **Surplus (deficit)** | **(350)** | **(354)** | **(383)** | **(359)** | **(354)** |
| **Surplus (deficit) attributable to the Australian Government** | **(350)** | **(354)** | **(383)** | **(359)** | **(354)** |
| **OTHER COMPREHENSIVE INCOME** |  |  |  |  |  |
| Changes in asset revaluation reserves | - | - | - | - | - |
| **Total other comprehensive income**  | **-** | **-** | **-** | **-** | **-** |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(350)** | **(354)** | **(383)** | **(359)** | **(354)** |
| **Note: Reconciliation of comprehensive income attributable to the agency** |
|  | **2021–22** $'000 | **2022–23** $'000 | **2023–24** $'000 | **2024–25** $'000 | **2025–26** $'000 |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(350)** | **(354)** | **(383)** | **(359)** | **(354)** |
| plus non-appropriated expenses depreciation and amortisation expenses | 356 | 370 | 410 | 340 | 343 |
| plus depreciation and amortisation expenses for RoU | 299 | 299 | 299 | 299 | 299 |
| less lease principal repayments | (305) | (315) | (326) | (280) | (288) |
| **Total comprehensive income (loss) attributable to the agency** | **-** | **-** | **-** | **-** | **-** |

RoU = Right-of-Use asset

Table 3.2: Budgeted Departmental Balance Sheet (as at 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **ASSETS** |  |   |  |  |  |
| **Financial assets** |  |   |  |  |  |
| Cash and cash equivalents | 268 | 268 | 268 | 268 | 268 |
| Receivables | 2,384 | 2,384 | 2,384 | 2,384 | 2,384 |
| **Total financial assets** | **2,652** | **2,652** | **2,652** | **2,652** | **2,652** |
| **Non-financial assets** |  |   |  |  |  |
| Land and buildings | 580 | 201 | 567 | 228 | 652 |
| Property, plant and equipment | 224 | 238 | 246 | 267 | 237 |
| Intangibles | 684 | 644 | 551 | 497 | 472 |
| Other | 121 | 121 | 121 | 121 | 121 |
| **Total non-financial assets** | **1,609** | **1,204** | **1,485** | **1,113** | **1,482** |
| **Total assets** | **4,261** | **3,856** | **4,137** | **3,765** | **4,134** |
| **LIABILITIES** |  |   |  |  |  |
| **Payables** |  |   |  |  |  |
| Suppliers | 410 | 410 | 410 | 410 | 410 |
| Other payables | 164 | 164 | 164 | 164 | 164 |
| **Total payables** | **574** | **574** | **574** | **574** | **574** |
| **Interest bearing liabilities** |  |   |  |  |  |
| Leases | 459 | 144 | 543 | 263 | 720 |
| **Total interest bearing liabilities** | **459** | **144** | **543** | **263** | **720** |
| **Provisions** |  |   |  |  |  |
| Employees | 961 | 961 | 961 | 961 | 961 |
| **Total provisions** | **961** | **961** | **961** | **961** | **961** |
| **Total liabilities** | **1,994** | **1,679** | **2,078** | **1,798** | **2,255** |
| **Net Assets** | **2,267** | **2,177** | **2,059** | **1,967** | **1,879** |
| **EQUITY** |  |   |  |  |  |
| Contributed equity | 3,941 | 4,205 | 4,470 | 4,737 | 5,003 |
| Reserves | 666 | 666 | 666 | 666 | 666 |
| Retained surpluses or (accumulated deficits) | (2,340) | (2,694) | (3,077) | (3,436) | (3,790) |
| **Total equity** | **2,267** | **2,177** | **2,059** | **1,967** | **1,879** |

Table 3.3: Departmental Statement of Changes in Equity – Summary of Movement (Budget year 2022–23)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Retained earnings** $'000 | **Asset revaluation reserve** $'000 | **Contributed equity/capital** $'000 | **Total equity** $'000 |
| **Opening balance as at 1 July 2022** |  |  |  |  |
| Balance carried forward from previous period | (2,340) | 666 | 3,941 | **2,267** |
| Surplus (deficit) for the period | (354) | - | - | **(354)** |
| Capital budget - Bill 1 (DCB) | - | - | 264 | **264** |
| **Estimated closing balance as at30 June 2023** | **(2,694)** | **666** | **4,205** | **2,177** |

DCB = Departmental Capital Budget

Table 3.4: Budgeted Departmental Statement of Cash Flows (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **OPERATING ACTIVITIES** |   |   |   |   |   |
| **Cash received** |  |   |  |  |  |
| Appropriations | 5,978 | 6,194 | 6,228 | 6,273 | 6,316 |
| Other | - | - | - | - | - |
| GST received | 195 | 165 | 165 | 200 | 200 |
| **Total cash received** | **6,173** | **6,359** | **6,393** | **6,473** | **6,516** |
| **Cash used** |  |   |  |  |  |
| Employees | 4,135 | 4,278 | 4,280 | 4,455 | 4,482 |
| Suppliers | 1,514 | 1,587 | 1,612 | 1,528 | 1,536 |
| Interest payments on lease liability | 14 | 14 | 10 | 10 | 10 |
| Other | 2 | - | - | - | - |
| GST paid | 203 | 165 | 165 | 200 | 200 |
| **Total cash used** | **5,868** | **6,044** | **6,067** | **6,193** | **6,228** |
| **Net cash from (or used by) operating activities** | **305** | **315** | **326** | **280** | **288** |
| **INVESTING ACTIVITIES** |  |   |  |  |  |
| **Cash used** |  |   |  |  |  |
| Purchase of property, plant and equipment | 261 | 264 | 265 | 267 | 266 |
| **Total cash used** | **261** | **264** | **265** | **267** | **266** |
| **Net cash from (or used by) investing activities** | **(261)** | **(264)** | **(265)** | **(267)** | **(266)** |
| **FINANCING ACTIVITIES** |  |   |  |  |  |
| **Cash received** |  |   |  |  |  |
| Capital budget - Bill 1 (DCB) | 261 | 264 | 265 | 267 | 266 |
| **Total cash received** | **261** | **264** | **265** | **267** | **266** |
| **Cash used** |  |   |  |  |  |
| Lease principal repayments | 305 | 315 | 326 | 280 | 288 |
| Other financing activity  | - | - | - | - | - |
| **Total cash used** | **305** | **315** | **326** | **280** | **288** |
| **Net cash from (or used by) financing activities** | **(44)** | **(51)** | **(61)** | **(13)** | **(22)** |
| **Net increase (or decrease) in cash held** | **-** | **-** | **-** | **-** | **-** |
| Cash and cash equivalents at the beginning of the reporting period | 268 | 268 | 268 | 268 | 268 |
| **Cash and cash equivalents at the end of the reporting period** | **268** | **268** | **268** | **268** | **268** |

DCB = Departmental Capital Budget

Table 3.5: Departmental Capital Budget Statement (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **CAPITAL APPROPRIATIONS** |   |   |   |   |   |
| Capital budget - Bill 1 (DCB) | 261 | 264 | 265 | 267 | 266 |
| Equity injections - Bill 2 | - | - | - | - | - |
| **Total capital appropriations** | **261** | **264** | **265** | **267** | **266** |
| **Total new capital appropriations represented by:** |   |   |  |   |   |
| Purchase of non-financial assets | 261 | 264 | 265 | 267 | 266 |
| **Total items** | **261** | **264** | **265** | **267** | **266** |
| **PURCHASE OF NON-FINANCIAL ASSETS** |   |   |  |   |   |
| Funded by capital appropriations - equity injection (a) | - | - | - | - | - |
| Funded by capital appropriation - DCB (b) | 261 | 264 | 265 | 267 | 266 |
| Funded internally from departmental resources | - | - | - | - | - |
| **Total acquisitions of non-financial assets** | **261** | **264** | **265** | **267** | **266** |
| **RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE** |  |   |  |  |  |
| Total purchases | 261 | 264 | 265 | 267 | 266 |
| **Total cash used to acquire assets** | **261** | **264** | **265** | **267** | **266** |

DCB = Departmental Capital Budget

(a) Includes both current Bill 2 and prior Act 2, 4, 6 appropriations.

(b) Does not include annual finance lease costs. Includes purchases from current and previous years’ DCB.

Table 3.6: Statement of Departmental Asset Movements (Budget year
2022–23)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Buildings** $'000 | **Property, plant and equipment** $'000 | **Intangibles** $'000 | **Total** $'000 |
| **As at 1 July 2022** |   |   |   |   |
| Gross book value  | 230 | 262 | 2,896 | **3,388** |
| Gross book value - RoU | 1,322 | - | - | **1,322** |
| Accumulated depreciation/amortisation and impairment | (74) | (38) | (2,212) | **(2,324)** |
| Accumulated depreciation/ amortisation and impairment - RoU | (898) | - | - | **(898)** |
| **Opening net book balance** | **580** | **224** | **684** | **1,488** |
| **CAPITAL ASSET ADDITIONS** |  |  |  |  |
| **Estimated expenditure on new or replacement assets** |  |  |  |  |
| By purchase - appropriation ordinary annual services | 50 | 50 | 164 | **264** |
| By purchase - RoU | - | - | - | **-** |
| **Total additions** | **50** | **50** | **164** | **264** |
| **Other movements** |  |  |  |  |
| Depreciation/amortisation expense | (130) | (36) | (204) | **(370)** |
| Depreciation/amortisation expense - RoU | (299) | - | - | **(299)** |
| Disposals (a) | - | - | - | **-** |
| **Total other movements** | **(429)** | **(36)** | **(204)** | **(669)** |
| **As at 30 June 2023** |  |  |  |  |
| Gross book value | 280 | 312 | 3,060 | **3,652** |
| Gross book value - RoU | 1,322 | - | - | **1,322** |
| Accumulated depreciation/ amortisation and impairment | (204) | (74) | (2,416) | **(2,694)** |
| Accumulated depreciation/ amortisation and impairment - RoU | (1,197) | - | - | **(1,197)** |
| **Closing net book balance** | **201** | **238** | **644** | **1,083** |

RoU = Right-of-Use asset

(a) Net proceeds may be returned to the Official Public Account.

**Table 3.7: Schedule of Budgeted Income and Expenses Administered on Behalf of Government (for the period ended 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| Grants | 43,532 | 43,882 | 44,594 | 45,744 | 46,538 |
| Supplier expenses | 4,749 | 5,249 | 5,488 | 5,265 | 5,201 |
| **Total expenses administered on behalf of Government** | **48,281** | **49,131** | **50,082** | **51,009** | **51,739** |

Table 3.8: Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government (as at 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| **Financial assets** |  |   |  |  |  |
| Cash and cash equivalents | 65 | 65 | 65 | 65 | 65 |
| Receivables | 11,389 | 11,389 | 11,389 | 11,389 | 11,389 |
| **Total financial assets** | **11,454** | **11,454** | **11,454** | **11,454** | **11,454** |
| **Non-financial assets** |  |  |  |  |  |
| Prepayments | 474 | 474 | 474 | 474 | 474 |
| **Total non-financial assets** | **474** | **474** | **474** | **474** | **474** |
| **Total assets administered on behalf of Government** | **11,928** | **11,928** | **11,928** | **11,928** | **11,928** |
| **LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| **Payables** |  |   |  |  |  |
| Grants | 11,241 | 11,241 | 11,241 | 11,241 | 11,241 |
| Suppliers | 240 | 240 | 240 | 240 | 240 |
| **Total payables** | **11,481** | **11,481** | **11,481** | **11,481** | **11,481** |
| **Total liabilities administered on behalf of Government** | **11,481** | **11,481** | **11,481** | **11,481** | **11,481** |

Table 3.9: Schedule of Budgeted Administered Cash Flows (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2021–22 Estimated actual**$'000 | **2022–23 Budget** $'000 | **2023–24 Forward estimate**$'000 | **2024–25 Forward estimate**$'000 | **2025–26 Forward estimate**$'000 |
| **OPERATING ACTIVITIES** |   |   |   |   |   |
| **Cash received** |  |   |  |  |  |
| GST received | 752 | 750 | 750 | 750 | 750 |
| Other | - | - | - | - | - |
| **Total cash received** | **752** | **750** | **750** | **750** | **750** |
| **Cash used** |  |   |  |  |  |
| Grant payments | 43,532 | 43,882 | 44,594 | 45,744 | 46,538 |
| Suppliers | 4,749 | 5,249 | 5,488 | 5,265 | 5,201 |
| GST paid | 752 | 750 | 750 | 750 | 750 |
| **Total cash used** | **49,033** | **49,881** | **50,832** | **51,759** | **52,489** |
| **Net cash from (or used by) operating activities** | **(48,281)** | **(49,131)** | **(50,082)** | **(51,009)** | **(51,739)** |
| **Net increase (or decrease) in cash held** | **(48,281)** | **(49,131)** | **(50,082)** | **(51,009)** | **(51,739)** |
| Cash at beginning of reporting period | 65 | 65 | 65 | 65 | 65 |
| Cash from the OPA for: |  |   |  |  |  |
| - appropriations | 49,033 | 49,881 | 50,832 | 51,759 | 52,489 |
| Cash to the OPA | (752) | (750) | (750) | (750) | (750) |
| **Cash at end of reporting period** | **65** | **65** | **65** | **65** | **65** |

OPA = Official Public Account

1. For more information about the strategic direction of the OTA, refer to the current Corporate Plan, available at: www.donatelife.gov.au/about-us/strategy-and-performance/corporate-plan [↑](#footnote-ref-1)
2. Performance measures are reported by calendar year to align with Australian and international donation and performance reporting practice. Annual data reports can be accessed at: www.donatelife.gov.au/about-us/data-and-research/data-reports [↑](#footnote-ref-2)
3. The COVID-19 pandemic has directly impacted the national program through increased patient risks from the virus, impact on hospitals and pandemic restrictions, reduction in commercial flights, and border closures, resulting in a decrease in donation and transplantation activity. [↑](#footnote-ref-3)
4. The COVID-19 pandemic has directly impacted the national program through increased patient risks from the virus, impact on hospitals and pandemic restrictions, reduction in commercial flights, and border closures, resulting in a decrease in donation and transplantation activity. Hospital restrictions requiring donation consent discussions with families to happen via tele- or videoconferencing rather than
face-to-face have contributed to the result. [↑](#footnote-ref-4)